書籍詳細

Part1 高血圧概論

P.25 掲載の参考文献

• 1) Kannel WB, Wilson PWF, Zhang T-J:The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 121:1268-1273, 1991

• 2) Ferrannini E, Natali A:Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J 121:1274-1282, 1991
  pubmed

• 3) Martin MJ, Hulley SB, Bowner WS et al:Serum cholesterol, blood pressure and mortality:implications from a cohort of 361, 662 men. Lancet ii:933-936, 1986

• 4) Samuelsson O, Wilhelmsen L, Andersson OK et al:Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the Primary Prevention Trial in Goteborg in Sweden. JAMA 258:1768-1776, 1987
  pubmed

• 5) Assmann G, Schulte H:The Prospective Cardiovascular Munster (PROCAM) study:Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 116:1713-1724, 1988

• 6) Ford ES, DeStefano J:Risk factors for from all causes and from coronary heart disease among persons with diabetes. Findings from the NHANES I. Epidemiologic follow-up Study. Am J Epidemiol 133:1220-1230, 1991

• 7) The Hypertension in Diabetes Study group:Hypertension in Diabetes Study (HDS):II. Incresed risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 11:319-325, 1993

• 8) Laws A, Marcus EB, Grove JS et al:Lipids and lipoproteins as a risk factors for coronary heart disease in men with abnormal glucose tolerance:the Honolulu Heart Program. J Intern Med 234:471-478, 1993

• 9) Hanefeld M, Schmechel H, Schwanebeck U et al:Predictors of coronary heart disease and death in NIDDM:the Diabetes Intervention Study experience. Diabetologia 40(suppl 2):S123-S124, 1997

• 10) Julius S, Jamarson K, Mejia A et al:The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure Study. JAMA 264:354-358, 1990

• 11) Laurenzi M, Mancini M, Menotti A et al:Multiple risk factors in hypertension:result from the Gubbio Study. J Hypertens 8(suppl 1):S7-S12, 1990

• 12) Bonaa KH, Thelle DS:Association between blood pressure and serum lipids in population. The Tromsφ study. Circulation 83:1305-1314, 1991

• 13) Weisser B, Grune S, Spuhler T et al:Plasma insulin is correlated with blood pressure only in subjects with family history of hypertension or diabetes mellitus:results from 11,001 participants in the Heureka Study. J Hypertens 11(suppl 5):S308-S309, 1993
  pubmed

• 14) Welborn TA, Breckenridge A, Rubinstein AH et al:Serum-insulin in essential hypertension and peripheral vascular disease. Lancet i:1336-1337, 1966
  pubmed

• 15) Modan M, Halkin H, Almog S et al:Hyperinsulinemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest 75:809-817, 1985
  pubmed

• 16) Reaven GM:Banting lecture 1988:Role of insulin resistance in human diseases. Diabetes 37:1595-1607, 1988
  pubmed

• 17) Haffner SM, Valdez RA, Hazuda HP et al:Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
  pubmed

• 18) Haffner SM, Mitchell BD, Stern MP et al:Decreased prevalence of hypertension in Mexican-Americans. Hypertension 16:225-232, 1990
  pubmed

• 19) Haffner SM, Ferrannini E, Hazuda HP et al:Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 20:38-45, 1992
  pubmed

• 20) Morales PA, Mitchell BD, Valdez RA et al:Incidence of NIDDM and impaired glucose in tolerance in hypertensive patients. The San Antonio Heart Study. Diabetes 42:154-161, 1993

• 21) Collins VR, Dowse GK, Finch CF et al:An inconsistent relationship between insulin and blood pressure in three Pacific island populations. J Clin Epidemiol 43:1369-1378, 1990
  pubmed

• 22) Dowse GK, Collins VR, Alberti KG et al:Insulin and blood pressure levels are not independently related in Mauritians of Asian Indian, Creole or Chinese origin. The Mauritius Non-communicable Disease Study Group. J Hypertens 11:297-307, 1993

• 23) Gray RS, Fabsitz RR, Cowan LD et al:Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. Am J Epidemiol 148:869-878, 1998
  pubmed

• 24) Saad MF, Lillioja S, Nyomba BL et al:Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 324:733-739, 1991
  pubmed

• 25) Falkner B, Hulman S, Tannenbaum J et al:Insulin resistance and blood pressure in young black men. Hypertension 16:706-711, 1990
  pubmed

• 26) Donahue RP, Donahue RA, Prineas RJ et al:Insulin sensitivity and blood pressure in a biethnic sample:the Miami Community Health Study. J Clin Epidemiol 49:859-864, 1996

• 27) Manolio TA, Savage PJ, Burke GL et al:Association of fasting insulin with blood pressure and lipids in young adults. The CARDIA study. Artriosclerosis 10:430-436, 1990
  pubmed

• 28) Haffner SM:Insulin and blood pressure:Fact or fantasy? J Clin Endocrinol Metab 76:541-543, 1993
  pubmed

• 29) Masuo K, Mikami H, Ogihara T et al:Differences in insulin and sympathetic nerve responses to glucose ingestion due to family history of hypertension. Am J Hypertens 9:739-745, 1996

• 30) Masuo K, Mikami H, Ogihara T et al:Do reduced insulin sensitivity and dyslipidemia exist in borderline hypertensive patients? Am J Hypertens 9:566-569, 1996
  pubmed

• 31) Masuo K, Mikami H, Ogihara T et al:Prevalence of hyper-insulinemia in young, non-obese Japanese men. J Hypertens 15:157-165, 1997

• 32) Masuo K, Mikami H, Ogihara T et al:Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, non-obese Japanese population. Am J Hypertens 10:77-83, 1997

• 33) Masuo K, Mikami H, Ogihara T et al:Familial hypertension, insulin, sympathetic activity, and blood pressure elevation. Hypertension 32:96-100, 1998
  pubmed

• 34) Skarfors ET, Lithell HO, Selinus I:Risk factors for the development of hypertension:a 10-year longitudinal study in middle aged men. J Hypertens 9:217-223, 1991

• 35) Lissner L, Bengtsson C, Lapidus L et al:Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 20:797-801, 1992
  pubmed

• 36) Laakso M:How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959-965, 1993

• 37) Asch S, Wingard DL, Barrett-Connor EL:Are insulin and hypertension independently related? Ann Epidemiol 1:234-244, 1991

• 38) Muller DC, Elahi D, Pratley RE et al:An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 76:544-548, 1993
  pubmed

• 39) Feskens JM, Loeber JG, Kromhout D:Diet and physical activity as determinants of hyperinsulinemia:The Zutphen study. Am J Epidemiol 140:350-360, 1994

• 40) Ramachandran A, Satyavani K, Snehalatha C et al:Clustering of cardiovascular risk factors in urban Asian Indians. Diabetes Care 21:967-971, 1998
  pubmed

P.34 掲載の参考文献

• 1) 築山久一郎, 大塚啓子:危険因子と高血圧合併症. 高血圧の臨床1996, 最新医学 51 (臨時増刊):626-635, 1996

• 2) Wilson PWF, Kannel WB:Hypertension, other risk factors, and the risk of cardiovascular disease. In:Hypertension:Pathophysiology, Diagnosis, and Management, 2nd ed, ed. by Laragh J H, Brenner BM, Raven Press, New York, 1995, pp.99-114

• 3) Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group:Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervntion Trial. JAMA 256:2823-2828, 1986

• 4) Janka HU, Warram JH, Rand LI et al:Risk factors for progression of background retinopathy in long-standing IDDM. Diabetes 38:460-464, 1989
  pubmed

• 5) Ritz E, Fliseer D, Nowicki M:Hypertention and Vascular Disease as Complications of Diabetes. In:Hypertension:Pathophysiology, Diagnosis, and Management, 2nd ed, ed. by Laragh JH, Brenner BM, Raven Press, New York,1995, pp.2321-2333

• 6) Borch-JK, Nissen H, Henriksen E et al:The natural history of insulin-dependent diabetes mellitus in Denmark:1. Long-term survival with and without late diabetic complications. Diabet Med 4:201-210,1987

• 7) Kreiger DR, Landsberg L:Obesity and hypertension. In:Hertension:Pathophysiology, Diagnosis, and Management, 2nd ed, ed. by Laragh JH, Brenner BM, Raven Press, New York, 1995, pp.2367-2388

• 8) Kannel WB, Zhang T, Garrion RJ:Is obesity related hypertension less of a cardiovascular risk? The Framigham Study. Am Heart J 120:1195-1201, 1990

• 9) Ramsay LE, Wallis EJ, Yeo WW et al:The rationale for differing national recommendations for the treatment of hypertension. Am J Hypertens 11:S79-S88, 1988

• 10) Langford HG, St amler J, Wassertheil-SS et al:All-cause mortality in the Hypertension Detection and Follow-up Program:findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis 29(suppl 1):S29-S54, 1986

• 11) Kannel WB:Risk factors in hypertension. J Cardiovasc Pharmacol 13(suppl 1):S4-S10, 1989

• 12) Anderson KM, Wilson PWF, Odell PM et al:An updated coronary risk profile. A statement for health professionals. Circulation 83:356-362, 1991

• 13) Ramsay LE:The hypertension detection and follow-up program:17 years on. JAMA 277:167-170, 1997
  pubmed

• 14) Core Service Committee:Guidelines for the management of Mildy Raised Blood Pressure in New Zealand, Wellington, New Zealand, 1995, pp.1-20

P.47 掲載の参考文献

• 1) The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, The National High Blood Pressure Education Program Coordinating Committee:The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997

• 2) European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Bihavioural Medicine, Society of General Practice/Family Medicine, European Heart Network:Prevention of coronary heart disease in clinical practice. Recommendation of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 19:1434-1503, 1998

• 3) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999
  pubmed

• 4) The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure:The Fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 153:154-183, 1993
  pubmed

• 5) Guidelines Sub-Committee:1993 Guideline for the management of mild hypertension:memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 11:905-918, 1993
  pubmed

• 6) Strasser T:Equal blood pressure levels carry different risks in different risk factor combinations. J Hum Hypertens 6:261-264, 1992
  pubmed

• 7) Sackett D:Guidelines for managing raised blood pressure. BMJ 313:64-65, 1996
  pubmed

• 8) Core Services Committee:Guidelines for the management of mildly raised blood pressure in New Zealand, Ministry of Health, Manatu Haura, 1995, pp.1-20

• 9) Pyorala K, De Backer G, Graham I et al, on behalf of the Task Force:Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiolongy, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15:1300-1331, 1994

• 10) National High Blood Pressure Education Program Working Group:National High Blood Pressure Education Program Working Group Report on hypertension in the elderly. Hypertension 23:75-285, 1994

• 11) Weber MA, Julius S:The challenge of very mild hypertension. Should treatment be sooner or later? Am J Hypertens 11:1495-1496, 1998
  pubmed

• 12) Hansson L, Zanchetti A, Carruthers SG et al, for the HOT Study Group:Effects of intensive blood-pressure lowring and low-dose aspririn in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351:1755-1762, 1998

• 13) UK Prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-713, 1998
  Medical*Online

• 14) Smith SC Jr, Blair SN, Criqui MH et al, the Secondary Prevention Panel:Preventing heart attack and death in patients with coronary heart disease. Circulation 92:2-4, 1995

• 15) Staessen JA, Fagard R, Thijs L et al, for the Systolic Hypertension in Europe Trial Investigators:Subgroups and per-protocol analysis of the randomized European trial on isolated syntolic hypertension in the elderly. Arch Intern Med 158:1681-1691, 1998

• 16) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
  pubmed

• 17) Amery A, Birkenhager W, Brixko R et al:Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet ii:589-592, 1986

• 18) 「老年者の高血圧治療ガイドライン作成に関する研究」班:治療対象と降圧目標. 老年者の高血圧治療ガイドライン1995 (長寿科学総合研究班試案), 厚生省長寿科学総合研究「老年者の高血圧治療ガイドライン作成に関する研究」班, 東京, 1995, pp.21-23

• 19) Grundy SM, Balady GJ, Criqui MH:Guide to primary prevention of cardiovascular dseases. A statement for healthcare professionals from the Task Force on Risk Reduction. Circulation 95:2329-2331, 1997

• 20) Psaty BM, Smith NL, Siscovick DS et al:Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277:739-745, 1997
  pubmed

• 21) CIBIS-II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomized trial. Lancet 353:9-13, 1999

• 22) Doughty R, Rodgers A, Sharpe N et al:Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 18:560-565, 1997

• 23) National High Blood Pressure Education Program Working Group:National High Blood Pressure Education Program Working Group Report on hypertension in diabetes. Hypertension 23:145-158, 1994

• 24) Estacio R, Jeffers BW, Hiatt WR et al:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
  pubmed

• 25) Taffi P, Pahor M, Byingron RB et al:Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998

• 26) Tuomilehto J, Rastenyte D, Birkenhager WH et al, for the Systolic Hypertension in Europe Trial Investigators:Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340:677-684, 1999
  pubmed

• 27) Pitt B, Sigal R, Martinez FA et al, on behalf of ELITE Study Investigators:Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly, ELITE). Lancet 349:747-752, 1997

• 28) Neaton JD, Grimm RH Jr, Prineas RJ et al, for the Treatment of Mild Hypertension Study Research Group:Treatment of Mild Hypertension Study. Final results. JAMA 270:713-724, 1993

• 29) Lewis CE, Grandits GA, Flack J et al, for the Treatment of Mild Hypertension Study Research Group:Efficacy and tolerance of antihypertensive treatment in men and women with stage I diastolic hypertension. Results of the Treatment of Mild Hypertension Study. Arch Intern Med 156:377-385, 1996

• 30) Guthrie R:Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia:aprimary care trial. J Fam Pract 39:129-133, 1994

P.56 掲載の参考文献

• 1) The National High Blood pressure Education Program Working Group:The National High Blood pressure Education Program Working Group Report on Hypertension in Diabetes. Hypertention 23:145-158, 1994

• 2) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2449, 1997
  pubmed

• 3) Stewart AL, Greenfield S, Hays RD et al:Functional status and well-being of patient with chronic condition. Result from the Medical Outcome Study. JAMA 262:907, 1989
  pubmed

• 4) Krolewski AS, Warram JH, Cupples A et al:Hypertension, orthostatic hypotension, and the microvascular complication of diabetes. J Chronic Dis 38:319-326, 1985
  pubmed

• 5) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595, 1988
  pubmed

• 6) Sowers JR:Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 29:691-699, 1997
  pubmed

• 7) Hausberg M, Hoffman RP, Somers VK et al:Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hypertension 29:700-705, 1997
  pubmed

• 8) Facchini FS, Stoohs RA, Reaven GM et al:Enhanced sympathetic nervous system activity. Am J Hypertens 9:1013-1017, 1996
  pubmed

• 9) Lind L, Berne C, Lithell H:Prevalence of insulin resistance in essential hypertension. J Hypertens 13:1457-1462, 1995
  pubmed

• 10) Estacio RO, Jeffers BW, Hiatt WR et al:The effect of nisoldipin as compared with enalapril on cardiovascular outcome in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
  pubmed

• 11) Tatti P, Pahor M, Byington R et al:Outcome results of the fosinopril versus amlodipine cardiovascular events randomised trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998
  pubmed

P.64 掲載の参考文献

• 1) Burt V, Cutler J, Higgins M et al:Trend in the prevalence, awareness, treatment, and control of hypertension in the adult US population:data from the health examination surveys. 1960 to 1991. Hypertension 26:60-69, 1995
  pubmed

• 2) Trial of Hypertension Prevention Collaborative Research Group:Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high normal blood pressure:The trials of hypertension prevention, phase II. Arch lntern Med 157:657-667, 1997

• 3) Cutler J, Follman D, Allender P:Randomized trials of sodium reduction:an overview. JAMA 275:1590-1597, 1997

• 4) Stamler J, Caggiula A, Grandis G:Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervension Trial. Am J Clin Nutr 65(suppl):S338-S365, 1997

• 5) Vedecchia P, Schillaci G, Boldrini F et al:Variability between current definitions of normal ambulatory blood pressure implications in the assessment of white coat hypertension. Hypertension 20:555-562, 1992

• 6) Mann S, Craig M, Refettery E:Superiority of 24 hour measurement of blood pressure in determining prognosis in hypertension. Clin Exp Hypertens A7:279-281, 1985

• 7) Verdecchia P, Porcellati C, Schillaci G et al:Ambulatory blood pressure:an independent predictor of prognosis in essential hypertension. Hypertension 24:793-801, 1994
  pubmed

• 8) The Joint National Committee:The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997

• 9) Cruickshank J:Coronary flow reserve and the J-curve relation between diastolic blood pressure and myocardial infarction. BMJ 297:1227-1230, 1988

• 10) Hansson L, Zanchetti A, Carruthers G et al:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 351:1755-1762, 1998

• 11) Rodgers A, MacMahon S, Gamble G et al:Blood pressure and risk of stroke in patients with cerebrovascular disease. The Unitid Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 313:147, 1996

• 12) Du X, Cruickshank K, McNamee R et al:Case-control study of stroke and the quarity of hypertension control in north west England. BMJ 314:272-276

• 13) Stamler J:Blood pressure and high blood pressure. Aspects of risk. Hypertension 18(suppl):S95-S107, 1991

• 14) Irie K, Yamazuchi T, Meiematsu K et al:The J-curve phenomenon in stroke recurrence. Stroke 24:1844-1849, 1993

• 15) Lewis E, Hunsicker L, Bain R et al:The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
  pubmed

• 16) Maki D, Ma JZ, Louis TA et al:Long term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155:1073-1080, 1995
  pubmed

• 17) Nony P, Boissel J, Girard P et al:Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure:implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure. Eur Heart J 13:1101-1108, 1992
  pubmed

• 18) Kiowsk W, Sutsch G, Dossegger L:Clinical benefit of angiotensin-converting enzyme inhibitors in chronic heart failure. J Cardiovasc Pharmacol 27(suppl 2):S19-S24, 1996

• 19) SHEP-cooperative-research-group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension in elderly program (SHEP) . JAMA 265:3255-3264, 1991

• 20) Dahlof B, Lindholm L, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension) . Lancet 338:1281-1285, 1991
  pubmed

• 21) Messerli F, Grossman E, Goldbourt U:Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903-1907, 1998
  pubmed

• 22) Staessen J, Fagard R, Thijs L et al:Randomized doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757-764, 1997
  pubmed

• 23) Gang L, Zhang W, Zhu Y et al:Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 14:1237-1245, 1996

• 24) Yusuf S, Peto R, Lewis J et al:Beta blockade during and after myocardial infarction:an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
  pubmed

• 25) Flather M, Lonn E, Yusuf S et al:Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction:evidence from the larger randomized controlled trials. J Cardiovasc Risk 2:423-428, 1995
  pubmed

• 26) Pfeffer M:ACE inhibitors in acute myocardial infarction:patient selection and timing. Circulation 97:2192-2194, 1998
  pubmed

• 27) Estacio R, Jeffers B, Hiatt W et al:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
  pubmed

• 28) Tatti P, Guarisco R, Pachor M et al:Outcome Result of the Fosinopril Versus Amlodipine Cardiovascular events Randmized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998

• 29) Kasiske B, Ma J, Kalil R et al:Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122:133-141, 1995

• 30) Levy D, Garrison R, Savage D et al:Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566, 1990
  pubmed

• 31) Muiesan M, Salvetti M, Rizzoni D et al:Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 13:1091-1095, 1995
  pubmed

• 32) Verdecchia P, Schillaci G, Borgioni C et al:Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48-54, 1998
  pubmed

• 33) Dahlof B, Pennert K, Hansson L:Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5:95-110, 1992
  pubmed

• 34) Neaton J, Grimm R, Prineas R et al:Treatment of mild hypertention:Final results. JAMA 270:713-724, 1993

• 35) Gottdiener JS, Reda D, Massie B et al:Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hyperetension:comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 95:2007-2014, 1997

• 36) Schiffrin E, Deng L, Larochelle P:Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 23:83-91, 1994

• 37) Thybo N, Stephens N, Cooper A et al:Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 25(suppl 1):S474-S481, 1995

• 38) Borhani N, Mercuri M, Borhani P et al:Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS) . A randomized controlled trial. JAMA 276:785-791, 1996
  pubmed

• 39) Zanchetti A, Rosei E, Palu C et al:The verapamil in hypertension and atherosclerosis study (VHAS):results of long-term randomized treatment with either verapamil or chlorthalidone on carotidintima-media thickness. J Hypertens 16:1667-1676, 1998

• 40) Mancini G, Henry G, Macaya C et al:Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 94:258-265, 1996
  pubmed

• 41) Iwatubo H, Nagano M, Sakai T et al:Converting enzyme inhibitor improves forarm reactive hyperemia in essential hypertension. Hypertension 29:286-290, 1997

• 42) Jachuck SJ, Brierley H, Jachuck S et al:The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 32:103-105, 1982
  pubmed

• 43) Croog S, Levine S, Testa M et al:The effects of antihypertensive therapy on the quality of life. N Engl J Med 314:1657-1664, 1986

• 44) Beto J, Bansal V:Quality of life in treatment of hypertension. A metaanalysis of clinical trials. Am J Hypertens 5:125-133, 1992
  pubmed

P.75 掲載の参考文献

• 1) Bulpitt CJ, Dollery CT, Carne S:Change in symptoms of hypertensive patients after referral to hospital clinic. Br Heart J 38:121-128, 1976
  pubmed

• 2) Cooper WD, Glover DR, Hormbrey JM et al:Headache and blood pressure:evidence of a close relationship. J Hum Hypertens 3:41-44, 1989
  pubmed

• 3) Tullio MD, Alli C, Avanzini F et al:Prevalence of symptoms generally attributed to hypertension or its treatment:study on blood pressure in elderly outpatients (SPAA) . J Hypertens 6(suppl 1):S87-S90, 1988

• 4) Cantillon P, Morgan M, Dundas R et al:Patients' perceptions of changes in their blood pressure. J Hum Hypertens 11:221-225, 1997
  pubmed

• 5) Haynes RB, Sackett DL, Taylor DW et al:Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 299:741-744, 1978
  pubmed

• 6) Strandgaard S, Paulson OB:Cerebral blood flow and its pathophysiology in hypertension. Am J Hypertens 2:486-492, 1989
  pubmed

• 7) Fraser R, Davies DL, Connell JMC:Hormones and hypertension. Clin Endocrinol 31:701-746, 1989

• 8) Gislason T, Benediktsdottir B, Bjoernsson JK et al:Snoring, hypertension, and the sleep apnea syndrome. An epidemiologic survey of middle-aged man. Chest 103:1147-1151, 1993

• 9) Hung J, Whitford EG, Parsons RW et al:Association of sleep apnoea with myocardial infarction in men. Lancet 336:261-264, 1990
  pubmed

• 10) Levinson PD, Millman RP:Causes and consequences of blood pressure alterations in obstructive sleep apnea. Arch Intern Med 151:455-462, 1991
  pubmed

• 11) Todd GPA, Chadwick IG, Yeo WM et al:Pressor effect of hyperventilation in healthy subjects(abstr). J Hypertens 11:1152, 1993

P.85 掲載の参考文献

• 1) The Joint National Committee:The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JNC-VI. Arch Intern Med 157:2413-2446, 1997

• 2) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17:151-183, 1999
  pubmed

• 3) Neaton JD, Grimm RH, Prineas RJ et al:Treatment of mild hypertension study (TOMHS):final results. JAMA 270:713-724, 1993

• 4) Wassertheil-Smoller S, Oberman AS, Blaufox MD et al:The trial of antihypertensive interventions and management (TAIM) study:final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 5:37-44, 1992

• 5) The TOHP Collaborative Research Group:The effect of nonpharmacologic interventions on blood pressure of persons with high normal levels:results of the Trials of Hypertension Prevention, phase I. JAMA. 267:1213-1220, 1992

• 6) Stamler J:Blood pressure and high blood pressure:aspects of risk. Hypertension 18 (suppl 1):S95-S107, 1991

• 7) Kannel WB:Blood pressure as a cardiovascular risk factor:prevention and treatment. JAMA 275:1571-1576, 1996
  pubmed

• 8) Stamler R, Stamler J, Gosch FC et al:Primary prevention of hypertension by nutritional-hygienic means:final report of a randomized, controlled trial. JAMA 262:1801-1807, 1989
  pubmed

• 9) Trial of Hypertension Prevention Collaborative Research Group:Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure:the Trial of Hypertension Prevention, phase II. Arch lntern Med 157:657-667, 1997

• 10) Appel LJ, Moore TJ, Obarzanek E et al:Aclinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 336:1117-1124, 1997

• 11) Hall WD, Ferrario CM, Moore MA et al:Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci 313:195-206, 1997
  pubmed

• 12) Sever P, Beevers G, Bulpitt C et al:Management guidelines in essential hypertension:report of the second working party of the British Hypertension Society. BMJ 306:983-987, 1993
  pubmed

• 13) Yoshida T, Sakane N, Umekawa T et al:Mutation ofβ? adrenergic-receptor gene and response to treatment of obesity. Lancet 346:1433-1434, 1995

• 14) Jha P, Flather M, Lonn E et al:The antioxidant vitamins and cardiovascular disease, a critical review of epidemiological and clinical trial data. Ann Intern Med 123:860-872, 1995
  pubmed

• 15) Kiyonaga A, Arakawa K, Tanaka H et al:Blood pressure and hormonal response to aerobic exercise. Hypertension 7:125-131, 1985
  pubmed

• 16) Whelton PK, Appel LD, Espelamd MA et al:Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled Trial of Nonpharmacologic Intervention in the Elderly (TONE) . IAMA 279:839-846, 1998

P.94 掲載の参考文献

• 1) 尾前照雄:1993年軽症高血圧管理のガイドラインWHO/ISH会議からの覚書. Ther Res 14:4682-4691, 1993

• 2) Joint National Committee on Detection, Evaluation, and Treatment of High Blood pressure:The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) . A rch Intern Med 153:154-183, 1993

• 3) 柊山幸志郎:高血圧の段階的治療法の再評価. 高血圧の基礎から臨床まで, 池田正男, 増山善明, 武田忠直ほか編, 診断と治療社, 東京, 1993, pp.548-555

• 4) 上原譽志夫:高血圧管理指針に影響の大きなmega trial. 臨床と薬物治療18:125-129, 1999

• 5) Siscovick DS, Raghunathan TE, Psaty BM et al:Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 330:1852-1857, 1994
  pubmed

• 6) 石井當男, 上原譽志夫:JNC VI (監訳) . Ther Res 18:3690-3742, 1997

• 7) Guidelines subcommittee:1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17:151-183, 1999
  pubmed

• 8) Gong L, Zhang W, Zhu Y et al:Shanghai Trial of Nifedipine in the Elderly (STONE) . J Hypertens 14 1237-1245, 1996

• 9) Staessen JA, Fagard R, Thijs L et al:Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757-764, 1997
  pubmed

• 10) Liu L, Wang JG, Gong L et al:Comparison of active treatment and placebo in older Chinese patinets with isolated hypertension. J. Hypertens 16:1823-1829, 1998

• 11) Hansson L, Zanchetti A, Carruthers SG et al:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998
  pubmed

• 12) Estacio RO, Jeffers BW, Hiatt WR et al:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
  pubmed

• 13) Tatti P, Pahor M, Byington RP et al:Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998
  pubmed

• 14) Staessen JA, Thijs L, Gasowski J et al:Treatment of isolated systolic hypertension in the elderly:further evidence from the Systolic Hypertension in Europe (Syst-Eur) trial. Am J Cardiol 82:20-22, 1998

• 15) Poulter NR:Calcium antagonists and the diabetic patient:a response to recent controversies. Am J Cardiol 82:40-41, 1998

• 16) UK Prospective Diabetes Study Group:Tight blood messure control and risk of macrovascular and microvascular complications:cations in type2 diabetes:UKPDS38. BMI 317:703-713, 1998

• 17) UK Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular compilications in type2 diabetes:UKPDS39. BMI 317:713-720, 1998

• 18) Forette F, Seux M-L, Staessen JA et al:Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352:1347-1351, 1998
  pubmed

• 19) Testa MA, Turner RR, Simonson DC et al:Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain. J Hypertens 16:1839-1847, 1998

P.103 掲載の参考文献

• 1) Shimamoto T, Komachi Y, Inada H et al:Trends for coronary heart disease and stroke and their risk factors in Japan. Circulation 79:503-515, 1989
  pubmed

• 2) Ramsay LE, Wallis EJ, Yeo WW et al:The rationale for differing national recommendations for the treatment of hypertension. Am J Hypertens 11:S79-S88, 1998

• 3) HDFP Hypertension Detection and Follow-up Program Cooperative Group:Five-year findings of the Hypertension Detection and Follow-up Program:1. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242:2562-2567, 1979

• 4) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
  pubmed

• 5) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) . Arch lntern Med 157:2413-2446, 1997

• 6) Ministry of Health:Guidelines for the Management of Mildly Raised Blood Pressure in New Zealand. Core Services Committee, Ministry of Health, Wellington, New Zealand, 1995

• 7) Pyorala K, De Backer G, Graham I et al:Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart/15:300-1331, 1994

• 8) Langford HG, Stamler J, Wassertheil-SS et al:All-cause mortality in the Hypertension Detection and Follow-up Program:findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis 29 (suppl 1):S29-S54, 1986

• 9) Leren P, Helgeland A, Hjermann I et al:The Oslo Study:CHD risk factors, socioeconomic influences and intervention. Am Heart J 106:1200-1206, 1983
  pubmed

• 10) Pool JL:Effects of doxazosin on serum lipids:areview of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 121:251-260, 1991

• 11) Neaton JD, Drimm RH, Prineas RJ et al:Treatment of mild hypertension Study. Final results. JAMA 270:713-723, 1993

• 12) Harano Y, Kageyama A, Hirose J et al:Improvement of insulin sensitivity for glucose metabolism with the long acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 44:315-319, 1995

• 13) Pitt B, Segal R, Martinez FA et al:Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly, ELITE) . Lancet 349:747-752, 1997
  pubmed

P.117 掲載の参考文献

• 1) Kanel WB:Hypertension as a risk factor for cardiac events-Epidemiologic results of long-term studies. J Cardiovasc Pharmacol 21 (suppl 2):S27-S37, 1993

• 2) Fagan TC, Deedwania PC:The Cardiovascular dysmetabolic syndrome. Am J Cardiol 105 (suppl I A):S77-S82, 1998

• 3) MacMahon S, Peto R, Cutler J et al:Blood pressure, stroke, and coronary heart disease. part I, prolonged differences in blood pressure:prospective observational studies corrected for the regression dilution bias. Lancet 335:765-774, 1990
  pubmed

• 4) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129mmHg. JAMA 202:1028-1034, 1967

• 5) Carter AB:Hypotensive therapy in stroke survivers. Lancet 1:485-489, 1970

• 6) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. II. Results of patients with diastolic blood pressure averaging 90 through 114mmHg. JAMA 213:1143-1151, 1970

• 7) Smith WM, for the US Public Health Service Hospitals Cooperative Study Group:Treatment of mild hypertension:Results of ten-year intervention trial. Circ Res 40 (suppl 1):S98-SIO5, 1977

• 8) Hypertension Detection and Follow-up Program Cooperative Group:Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure including, mild hypertension. JAMA 242:2562-2571, 1979
  pubmed

• 9) Helgeland A:Treatment of mild hypertension:A five-year controlled drug trial. Am J Med 69:725-732, 1980
  pubmed

• 10) Report by the Management Committee:The Australian therapeutic trial in mild hypertension. Lancet i:1261-1267, 1980

• 11) Medical Research Council Working Party:MRC trial of treatment of mild hypertension:PrincipaI results. BMJ 291:97-104, 1985

• 12) Multiple Risk Factor Intervention Trial Research Group:Multiple Risk Factor Intervention Trial:Risk factor changes and mortality results. JAMA 248:1465-1477, 1982

• 13) Amey A, Brikenhager W, Brixko P et al:Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet i:1349-1354, 1985

• 14) MacMahon SW, Cutler JA, Furberg CD et al:The effect of drug treatment for hypertension on morbidity and mortality from cardiovascular disease:a review of randomized controlled trials. Prog Cardiovasc Dis 29 (suppl I):S99-S118, 1986

• 15) Collins R, Peto R, MacMahon S et al:Blood pressure, stroke, and coronary heart disease. part 2. Short-term reductions in blood pressure:overview of randomised drug trials in their epidemiological context. Lancet 335:827-838, 1990
  pubmed

• 16) Peto R, Yusuf S, Collins R:Cholesterol-lowering trial results in their epidemiologic context (abstrt) . Circulation 72 (suppl III):451, 1985

• 17) SHEP Cooperative Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. IAMA. 265:3255-3264, 1991

• 18) MRC working Party:Medical Reserarch Council trial of treatment of hypertension in older adults:principal results. BMJ 304:405-411, 1992

• 19) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) . Lancet 338:1281-1285, 1991
  pubmed

• 20) Thijs L, Fagard R, Lijnen P et al:A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 10:1103-1109, 1992
  pubmed

• 21) Messerli FH, Grossman E, Goldbourt U:Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903-1907, 1998

• 22) The Joint National Committee:The Sixth Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997

• 23) Staessen JA, Fagard R, Thijs L et al, for the systolic Hypertension-Europe (Syst-Eur) Trial Invenstigators:Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet 360:757-764, 1997

• 24) Gong L, Zhang W, Zhu Y et al:Shanghai Trial of Nifedipine in the Elderly (STONE) . J Hypertens 14:1237-1245, 1996

• 25) Stanton A:Calcium channel blockers. BMI 316:1471-1473, 1998

• 26) Byington RP, Craven T, Furberg CD et al:raised glycosylated hemoglobin, and risk of cardiovascular events. Lancet 350:1075-1076, 1997
  pubmed

• 27) Estacio RO, Jeffers BW, Hiatt WR et al:The effect of nisoldipine as comared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998

• 28) The SOLVD Investigators:Effect of enalapril on survival in patients with reducer left ventricular ejection farctions and congestive heart failure. N Engl J Med 325:293-303, 1991

• 29) Yusuf S, Pepine CJ, Garces C et al:Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340:1173-1178, 1992
  pubmed

• 30) Sawicki PT:Do ACE inhibitors offer specific benefits in the antihypertensive treatment of diabetic patients? 17 years of unfulfilled promises. Diabetologia:598-602, 1998
  pubmed

• 31) Lacourciere Y, Nadeau A, Poirier L et al:Captopril or conventional therapy in hypertensive type 2 diabetics. Three-year analysis. Hypertension 21:786-794, 1993

• 32) UK Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS39. BMI 17:713-720, 1998

• 33) Barry RD, Jeffrey AC, David J et al, for the ALLHAT Research Group:Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Am J Hypertens 9:342-360, 1996

• 34) Cruickschank JM, Thorp JM, Jacharias FJ:Benefit and potential harm of lowering high blood pressure. Lancet i:581-584, 1987

• 35) D' Agostino RB, Belanger AJ, Kannel WB et al:Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction. BMJ 303:385-389, 1991
  pubmed

• 36) MacMahon S, Rodgers A, Neal B et al:Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertention 29:537-538, 1997

• 37) Flack JM, Neaton J, Grim R et al, for the Multiple Risk Factor Intervention Trial Research Group:Blood pressure and mortality among men with prior myocardial infarction. JAMA 242:2572-2577, 1979

• 38) Burt VL, Whelton P, Roccella E et al:Prevalence of hypertension in the US adult population. Results from the third National Health and Nutrition Examination Survey, 1988-1991. HLypertension 25:305-313, 1995
  pubmed

• 39) Hannson L, Zanchetti A, Carruthers SG et al, for the HOT study Group:Effects of intensive bloodpressur lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998

• 40) Kaplan N:J-curve not burned off by HOT study. Lancet 351:1748-1749, 1998

• 41) UK prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS38. BMJ 317:703-713, 1998
  Medical*Online

P.127 掲載の参考文献

• 1) Hansson L, Zanchetti A, Carruthers SG et al:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised Trial. Lancet 351:1755-1762, 1998
  pubmed

• 2) Staessen JA, Fagard R, Thijs L et al:Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757-774, 1997
  pubmed

• 3) Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure:The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI) . Arch lntern Med 157:2413-2446, 1997

• 4) Widmann L, van der Does R, Horrmann L et al:Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide. Eur J Clin Pharmacol 38 (suppl 2):S143-S146, 1990

• 5) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) . Lancet 338:1281-1285, 1991
  pubmed

• 6) SHEP Cooperative Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final result of the Systolic Hypertension in the Elderly Program (SHEP) . JAMA 265 3255-3264, 1991

• 7) Monmany J, Domingo P, Gomez JA et al:Effects of long-term treatment with metoprolol and hydrochlorothiazide on plasma lipids and lipoproteins. J Intern Med 228:323-331, 1990
  pubmed

• 8) Hoes AW, Grobbee DE, Lubsen J et al:Diuretics, β-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 123:481-487, 1995

• 9) Hosie J, Dahlof B, Klein G:The long-term antihypertensive efficacy and safety of a new felodipine-metoprolol combination tablet. The Swedish/UK and German Study Groups. Bloodd Press 1 (suppl 1):S46-S50, 1993

• 10) Franz IW, Tonnesmann U, Behr U et al:Regression of left ventricular hypertrophy by acebutolol and nifedipine. Cardiovasc Drugs Ther 3:313-317, 1989
  pubmed

• 11) Wetzchewald D, Klaus D, Garanin G et al:Regression of left ventricular hypertrophy during long-term antihypertensive treatment:acomparison between felodipine and the combination of felodipine and metoprolol J Intern Med 231:303-308, 1992

• 12) Pordy RC:Cilazapril with adjunctive hydrochlorothiazide:analysis of safety and efficacy in hypertensive patients not responding to cilazapril alone. Cardiology 86:41-48, 1995

• 13) Ishimitsu T, Yagi S, Ebihara A et al:Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension. Jpn Heart J 38:831-840, 1997

• 14) Lacourciere Y, Gagne C:Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypertension. J Hum Hypertens 7:149-152, 1993
  pubmed

• 15) Clarke PF, Kendall R, Hornby R et al:Captopril and hydrochlorothiazide:asafe antihypertensive for use in general practice? J Clin Pharm Ther 16:361-366, 1991

• 16) Tobian L, Brunner HR, Cohn JN et al:Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from JNC V consensus guidelines.Am J Hypertens 7:859-872, 1994
  pubmed

• 17) Eggertsen R, Svensson A, Dahlof B et al:Additive effect of isradipine in combination with captopril in hypertensive patients. Am J Med 86:124-126, 1989
  pubmed

• 18) Ferrier C, Ferrari P, Weidmann P et al:Antihypertensive therapy with Ca2+ antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care 14:911-914, 1991
  pubmed

• 19) Epstein M:The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure:focus on fixed-dose combination antihypertensive therapy. Ren Fail 18:813-832, 1996
  pubmed

• 20) Pfeffer MA, Braunwald E, Moye LA et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction:results of the Survival And Ventricular Enlargement Trial. N Engl J Med 327:69-677, 1992

• 21) The SOLVD investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
  pubmed

• 22) Andersson R, Blomstrom-Lundgvist C, Hender T et al:Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol 18:1059-1066, 1991

• 23) Ishimitsu T, Yagi S, Sugishita T et al:Long-term effects of doxazosin, an α1-blocker, on serum lipids in hypertensive patients. Hypertens Res 19:43-49, 1996

• 24) Gavras HP, Salerno CM:The angiotensin II type 1 receptor blocker losartan in clinical practice:a review. Clin Ther 18:1058-1067, 1996
  pubmed

• 25) Tiebel R, Vahlbruch A, Stapff M:Efficacy, Safety, and effects on hypertension-associated symptoms of losartan, alone or in combination with hydrochlorothiazide, versus amlodipine in patients with mild-to-moderate hypertension. Curr Ther Res 59:325-340, 1998

• 26) Nakashima M, Uematsu T, Kosuge K et al:Pilot Study of the uricosuric effect of Dup-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42:333-335, 1992
  pubmed

• 27) Schmitt F, Natov S, Martinez F et al:Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man. Clin Sci 90:205-213, 1996
  pubmed

• 28) Azizi M, Guyene T-T, Chatellier G et al:Additive effects of losartan and enalapril on blood pressure and plasma active renin.Hypertension 29:634-640, 1997
  pubmed

P.134 掲載の参考文献

• 1) Rett K, Wicklmayr M, Dietze GJ et al:Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides and captopril. N Engl J Med 319:1609, 1988
  pubmed

• 2) Shor RI, Ray W, Daugherty JR et al:Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 278:40-43, 1997
  pubmed

• 3) Pollare T, Lithell H, Berne C:A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873, 1989

• 4) Kodama J, Katayama S, Tanaka K et al:Effects of captopril on glucose metabolism. Possible role of augmented postprandial forearm blood flow.Diabetes Care 13:1109-1111, 1990
  pubmed

• 5) Katayama S, Inaba M, Maruno Y et al:Glucose intolerance in spontaneously hypertensive and Wistar-Kyoto rats:Enhanced gene expression and synthesis of skeletal muscle glucose transporter 4. Hypertens Res 20:279-286, 1997
  pubmed

• 6) Chen S, Noguchi Y, Izumida T et al:A comparison of the hypotensive and hypoglycemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J Hypertens 14:1325-1330, 1996
  pubmed

• 7) Devis G, Somers G, Van Obberghen E et al:Calcium antagonists and islet function. 1. Inhibition of insulin release by verapamil. Diabetes 24:547-551, 1975

• 8) Bhatnagar SK, Amin MMA, Al-Yusuf AR:Diabetogenic effects of nifedipine. BMJ 289:19-20, 1984

• 9) Lind L, Berne C, Pollare T et al:Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide:adouble-blind, cross-over study.J Hum Hypertens 9:137-141, 1995
  pubmed

• 10) Giordano M, Matsuda M, Sanders L et al:Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 44:665-671, 1995

• 11) Harano Y, Kageyama A, Hirose J et al:Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 44:315-319, 1995

• 12) Kosegawa I, Inaba M, Morita T et al:Effect of the vasodilatory β-blocker, nipradilol, and Caantagonists, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens 20:751-761, 1998

• 13) Pollare T, Lithell H, Morlin C et al:Metabolic effects of diltiazem and atenolol:results from a randomized, double-blind study with parallel groups. J Hypertens 7:551-559, 1989
  pubmed

• 14) Moan A, Hoieggen A, Seljeflot I et al:The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 14:1093-1097, 1996
  pubmed

• 15) Laakso M, Karjalainen L, Lempiainen-Kuosa P:Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 28:392-396, 1996
  pubmed

• 16) Paolisso G, Tagliamonte MR, Gambardella A et al:Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose meatbolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 11:307-312, 1997

• 17) Landin K, Tengborn L, Smith U:Treating insullin resitance in hypertension with metformin reduces both blood pressure and metabolic factors. J Intern Med 229:181-187, 1991

• 18) Ogihara T, Rakugi H, Ikegami H et al:Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertension. Am J Hyperntens 8:316-320, 1995

• 19) Nolan JJ, Ludvik B, Beerdersen P et al:Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
  pubmed

P.142 掲載の参考文献

• 1) Kannel WB, Dawber TR:Hypertension as an ingradient of a cardiovascular risk profile. Br J Hosp Med 2:508-514, 1974

• 2) 松澤佑次, 久道茂, 北徹ほか:わが国の勤労者における脳心事故の発症要因とその出現時期および持続時間に関する症例対照研究. 労働省作業関連疾患総合対策研究. 宿主要因と動脈硬化性疾患に関する研究班報告, 東京, 1995, pp.1-41

• 3) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. JAMA 213:1143-1152, 1970

• 4) Helgeland A:Treatment of Mild Hypertension. A five year controlled drug trial. The Oslo Study. Am J Med 69:725-732, 1980
  pubmed

• 5) Medical Research Council Working Party:MRC trial of treatment of mild hypertension:principal results. BMJ 291:97-104, 1985
  pubmed

• 6) The IPPPSH Collaborative Group:IPPPSH Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol:the International Prospective Primary Prevention Study in Hypertension (IPPPSH) . J Hypertens 3:379-392, 1985

• 7) Wikstrand J, Warnold I, Olsson G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY Study. JAMA 259:1976-1982, 1988
  pubmed

• 8) The GLANT Study Group:A 12-month comparison ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension. The GLANT Study. Hypertens Res 18:235-244, 1995

• 9) Staessen JA, Thijs L, Fagard RH et al:Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 32:410-416, 1998
  pubmed

• 10) Estacio RO, Jeffers BW, Hiatt WR et al:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
  pubmed

• 11) The HOT Study Group:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998

• 12) Grimm RH Jr, Flack JM, Grandits GA et al:Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 275:1549-1556, 1996

• 13) Davis BR, Cutler JA, Gordon DJ et al:Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) . ALLHAT Research Group. Am J Hypertens 9:342-360, 1996

• 14) Levy D, Walmsley P, Levenstein M:Principal results of the Hypertension and Lipid Trial (HALT):a multicenter Study of doxazosin in patients with hypertension. Am Heart J 131 966-973, 1996

• 15) Ferrara LA, Di-Marino L, Russo O et al:Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensive Study. Hypertension 21:97-104, 1993

• 16) Wilhelmsen L, Berglund G, Elmfeldt D et al:Beta-blockers versus diuretics in hypertensive men:main results from the HAPPHY trial. J Hypertens 5:561-572, 1987

• 17) Pahor M, Guralnik JM, Corti MC et al:Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 43:1191-1197, 1995

• 18) Gong L, Zhang W, Zhu Y et al:Shanghai trial of nifedipine in the elderly (STONE) . J Hypertens 14:1237-1245, 1996

• 19) PATS Collaborating Group:Post-stroke antihypertensive treatment Study. A preliminary result. Clin Med J 108:710-717, 1995

• 20) Hypertension-Stroke Cooperative Study Group:Effect of antihypertensive treatment on stroke recurrence. JAMA 229:409-418, 1974

• 21) PROGRESS:Management Committee:Blood pressure lowering for the secondary prevention of stroke:rationale and design for PROGRESS. Perindopril Protection Against Recurrent Stroke Study. J Hypertens 14 (suppl):S41-S46, 1996

• 22) Olsson G, Rehnqvist N, Sjogren A et al:Long-term treatment with metoprolol after myocardial infarction:effect on 3 year mortality and morbidity. J Am Coll Cardiol 5:1428-1437, 1985
  pubmed

• 23) A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247:1707-1714, 1982
  pubmed

• 24) Australia/New Zealand Heart Failure Research Collaborative Group:Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349:375-380, 1997

• 25) Pfeffer MA, Braunwald E, Moye LA et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 327:669-677, 1992

• 26) Kφber L, Torp-Pedersen C, Carlsen JE et al:A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:1670-1676, 1995

• 27) Swedberg K, Held P, Kjekshus J et al:Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) . N Engl J Med 327:678-684, 1992

• 28) The Multicenter Diltiazem Postinfarction Trial Research Group:The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 319:385-392, 1988

• 29) Packer M, O'Connor CM, Ghali JK:Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 335:107-1114, 1996

• 30) Cohn JN, Archibald DG, Ziesche S et al:Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314:1547-1552, 1986

• 31) Boissel JP, Leizorovicz A, Picolet H et al:Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol 66:251-260, 1990
  pubmed

• 32) The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators:Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828, 1993

• 33) ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group:ISIS-4:a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58, 050 patients with suspected acute myocardial infarction. Lancet 345:669-685, 1995

• 34) CCS Collaborative Group:Oral captopril versus placebo among 13, 634 patients with suspected acute myocardial infarction:interim report from the Chinese Cardiac Study (CCS-1) . Lancet 345:686-687, 1995

• 35) The Danish Study Group on Verapamil in myocardial Infarction:Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II DAVIT II) . Am J Cardiol 66:779-785, 1990

Part 2 α遮断薬の臨床評価と有用性

P.168 掲載の参考文献

• 1) Cambridge D, Davey MJ, Massingham R:Prazosin. A selective antagonist of post-synaptic α-adrenoceptors. Brit J Pharmacol 59:514-515, 1977

• 2) Leren P, Foss OP, Helgeland A et al:Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lanset ii:4-6, 1980

• 3) Pollare T, Lithell H, Selinus I et al:Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 31:415-420, 1988
  pubmed

• 4) 山口脩, 白岩康夫, 小林正人ほか:前立腺肥大症に伴う排尿障害に対する塩酸プラゾシン錠 (ミニプレス錠) の臨床評価-多施設共同によるパラプロストカプセルとの二重盲験比較試験. 医学と薬学 19:411-429, 1988

• 5) van Zwieten PA:Pharmacological and haemodynamic profile of urapidil. Treatment of hypertension with urapidil. In:Preclinical and clinical update, Royal Society of Medical Services, London, 1986, pp.1-9

• 6) Brogden RN, Heel RC, Speight TM et al:Prazosin:A review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14:163-197, 1977
  pubmed

• 7) 三浦幸雄:α1遮断薬-腎障害を伴う高血圧患者における有用性. 腎と透析39 (増刊号):538-545, 1995

• 8) Vanhoutte PM:Heterogeneity of postjunctional vascular α-adrenoceptors and handling of calcium. J Cardiovasc Pharmacol 4 (suppl 1):S91-S96, 1982

• 9) Vincent J, Dachman W, Blaschke TF et al:Pharmcological tolerance to α1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest 90:1763-1768, 1992

• 10) 吉永馨, 三浦幸雄, 金子好宏ほか:本態性高血圧症に対する塩酸テラゾシンの長期投与における有効性と安全性の検討. 薬理と治療15:2835-2860, 1987

• 11) 林博史, 兼松克己, 鵜飼雅彦ほか:Terazosinの本態性高血圧症に対する降圧効果と血圧日内リズムに及ぼす影響. Prog Med 12:1351-1358, 1992

• 12) Pickering TG, Levenstein M, Walmsley P:Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT study. Am J Hypertens 7:844-847, 1994
  pubmed

• 13) 江畑均, 北条行弘, 池田宇一ほか:血圧日内変動に対するメシル酸ドキサゾシン (カルデナリン錠) の効果-DipperおよびNon-dipperタイプ夜間高血圧に対するα1-blockerの効果-. Ther Res 15:1213-1219, 1994

• 14) Agabiti-Rosei E, Muiesan L, Rizzoni D et al:Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin. J Hum Hpertens 6:9-15, 1992

• 15) Neaton JD, Grimm RH Jr, Prineas RJ et al:Treatment of mild hypertension study. Final results. JAMA 270:713-724, 1993
  pubmed

• 16) Miura Y, Watanabe M, Yoshinaga K:An evaluation of the efficacy and safety of doxazosin in hypertension associated with renal dysfunction. Am Heart J 121:381-388, 1991
  pubmed

• 17) 林晃一:腎疾患とα遮断薬. 血圧 11:1152-1157, 1998
  Medical*Online

• 18) 鹿野昌彦, 川島司郎, 青木孝彦ほか:糖尿病患者に対するdoxazosinの効果-早期糖尿病性腎症とインスリン感受性についての検討-. 医学と薬学33:453-457, 1995

• 19) 三浦幸雄:糖尿病, 血清脂質異常を合併する高血圧患者に対するメシル酸ドキサゾシンの有用性. Ther Res 15:1221-1232, 1994

• 20) Shionoiri H, Gotoh E, Ito T et al:Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives:A multicenter prospective study. Am J Med Sci 307 (suppl 1):S91-S95, 1994

• 21) Lithell H:Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14:203-209, 1991
  pubmed

• 22) Levy D, Wilson PWF, Anderson KM et al:Stratifying the patient at risk from coronary disease:new insights from the Framingham Heart Study. Am Heart J 119:712-717, 1990

• 23) 増淵和男, 斎藤友昭, 河村博ほか:塩酸テラゾシンによる降圧治療における血清脂質に対する影響. 臨牀と研究69:3337-3346, 1992

• 24) Pool JL:Effects of doxazosin on serum lipids:A review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 121:251-260, 1991
  pubmed

• 25) Hernandez RH, Pajuelo JRG, Carvajal AR et al:Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension. an ex vivo study. Am Heart J 121:395-401, 1991

• 26) Gomi T, Ikeda T, Ikegami F:Beneficial effect ofα-blocker on hemorheology in patients with essential hypertension. Am J Hypertens 10:886-892, 1997

• 27) 熊本悦明, 塚本泰司, 八竹直ほか:前立腺肥大症に伴う排尿障害に対する塩酸テラゾシンの臨床評価 (II) -プラセボを対照薬とした二重盲験比較試験-. 泌尿器外科 5:823-840, 1992

• 28) 三浦幸雄:α遮断薬服用者が留意すべき相互作用. 臨床と薬物治療 15:28-30, 1996

• 29) Seideman P, Grahnen A, Haglund K et al:Prazosin first dose phenomenon during combined treatment with beta-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol 13:865-870, 1982
  pubmed

P.178 掲載の参考文献

• 1) The Joint National Committee on Prevention, Detection, Evaluation, and Treatment on High Blood Pressure:The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI) . Arch lntern Med 157:2413-2446, 1997

• 2) Leren P, Foss PO, Helgeland A:Effect of propranolol and prazosin on blood lipids:The Oslo Study. Lancet 2:4-6, 1980
  pubmed

• 3) Kasiske BL, Ma JZ, Kalil RS et al:Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122:133-141, 1995

• 4) Neaton JD, Grimm RH Jr, Prineas RJ et al:Treatment of mild hypertension study. Final results.JAMA 270:713-724, 1993
  pubmed

• 5) Grimm RH, Flack JM, Grandits GA et al:Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 275 1549-1556, 1996
  pubmed

• 6) Levy D, Walmsley P, Levenstein M:Principal results of the hypertension and lipid trial (HALT):A multicenter study of doxazosin in patients with hypertension. Am Heart J 131:966-973, 1996

• 7) Pollare T, Lithell H, Selinus I et al:Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 31:415-420, 1988
  pubmed

• 8) Lithell HO:Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14:203-209, 1991
  pubmed

• 9) Giordano M, Matsuda M, Sanders L et al:Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 44:665-671, 1995

• 10) Andersson P-E, Lithell H:Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J Hypertens 9:323-333, 1996
  pubmed

• 11) Ferrara LA, Di Marino L, Russo O et al:Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients:The doxazosin-captopril in hypercholesterolemic hypertensives study. Hypertension 21:97-104, 1993

• 12) Grimm RH, Grandits GA, Prineas RJ et al:Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women:Treatment of Mild Hypertension Study (TOMHS). Hypertension 29:8-14, 1997
  pubmed

P.186 掲載の参考文献

• 1) Muratani H, Fukiyama K, Kamiyama T et al:Current status of antihypertensive therapy for elderly patients in Japan. Hypertens Res 19:281-290, 1996

• 2) Guidelines Sub-committee:1993 Guidelines for the management of mild hypertension:Memorandum from a World Health Organization/International Society of Hypertension meeting. J Hyepertens 11:905-918, 1993
  pubmed

• 3) Joint National Committee:The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC VI). Arch Intern Med 157:2413-2449, 1997

• 4) Donnelly R, Elliott HL, Howie CA et al:Vascular pressor responses in treated and untreated essential hypertension. J Cardiovasc Pharmacol 16:191-196, 1990
  pubmed

• 5) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
  pubmed

• 6) Ferrannini E, Buzzigoli G, Bonadonna R et al:Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
  pubmed

• 7) Lithell HOL:Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14:203-209, 1991

• 8) Yamasaki Y, Shiba Y, Sekiya M et al:Selective alpha 1-adrenergic inhibition improves decreased glucose disposal in patients with essential hypertension. J Hum Hypertens 8:555-558, 1994
  pubmed

• 9) Giorda C, Appendino M, Mason MG et al:α1-Blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism 44:673-676, 1995

• 10) Kasiske BL, Ma JZ, Kalil RSN et al:Effects of antihypertensive therapy on serum lipids. Ann lntern Med 122:133-141, 1995

• 11) Ferrara LA, Marino LD, Russo O et al:Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension 21:97-104, 1993

• 12) Levy D, Walmsley P, Levenstein M:Principal results of the hypertension and lipid trial (HALT):A multicenter study of doxazosin in patients with hypertention. Am Heart J 131:966-973, 1996

• 13) Daae LNW, Westlie L:A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension:Effects on blood pressure, serum lipids, and coronary heart disease risk. Blood 1) ress 7:39-45, 1998

• 14) Kirby RS, Pool JL:Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia:past, present and furture. Br J Urol 80:521-532, 1997

• 15) Gillenwater JY, Conn RL, Chrysant SG et al:Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension:adouble-blind, placebo controlled, dose-response multicenter study. J Urol 154:110-115, 1995

• 16) Debruyne FMJ, Witjes WPJ, Fitzpatrick J et al:The International Terazosin Trial:A multicenter study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyper:plasia. Eur Urol 30:369-376, 1996

• 17) Pickering TG, Levenstein M, Walmsley P:Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Result of the HALT Study. Am J Hypertens 7:844-847, 1994
  pubmed

• 18) Ebata H, Hojo Y, Ikeda U et al:Differential effects of an α1-blocker (doxazosin) on diurnal blood pressure variation in dipper and non-dipper type hypertension. Hypertens Res 18:125-130, 1995

• 19) Kawano Y, Tochikubo O, Watanabe Y et al:Doxazosin suppresses the morning increase in blood pressure and sympathetic nervous activity in patients with essential hypertension. Hypertens Res 20:149-156, 1997
  pubmed

• 20) Kaplan NM:Pheochromocytoma (with a Preface about Incidental Adrenal Masses). In:Clinical Hypertension, 7th ed, ed. by Williams B & Wilkins B, Balimore, 1998, pp.345-363

• 21) Carruthers SG:Adverse effects of α1-adrenergic blocking drugs. Drug Saf 11:12-20, 1994

• 22) 柊山幸志郎, 川副信行:αプロッカーの副作用. αプロッカーの臨床, II. 臨床編, 尾前照雄監修, メディカルレビュー社, 大阪, 1990, pp.112-116

• 23) Fulton B, Wagstaff AJ, Sorkin EM:Doxazosin. An update of its clinical phamacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 49:95-320, 1995

• 24) 荻原俊男, 森本茂人, 中橋毅ほか:本邦における老年者高血圧に対する治療方針に関する検討. 日老医誌 31:396-403, 1994

• 25) Grimm RH Jr, Grandits GA, Prineas RJ et al:Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOHMS). Hypertension 29:8-14, 1997
  pubmed

P.194 掲載の参考文献

• 1) Casiglia E, Palatini P, Colangeli G et al:24h rhythm of blood pressure and forearm peripheral resistance in normotensive and hypertensive subjects confined to bed. J Hum Hypertens 14:47-52, 1996

• 2) Sternberg H, Rosenthal T, Shamiss A et al:Altered circadian rhythm of blood pressure in shift workers. J Hum Hypertens 9:349-353, 1995
  pubmed

• 3) Kuwajima I, Mitani K, Miyano M et al:Cardiac implications of morning surge in blood pressure in elderly hypertensive patients:Relation to arising time. Am J Hypertens 8:29-33, 1995

• 4) Kobrin I, Oigman W, Kumar A et al:Diurnal variation of blood pressure in elderly patients with essential hypertension. J Am Geriatr Soc 32:896-899, 1984
  pubmed

• 5) Shimada K, Kawamoto A, Matsubayashi K et al:Silent cerebrovascular disease in the elderly:Correlation with ambulatory pressure. Hypertension 16:692-699, 1990
  pubmed

• 6) Zakopoulos N, Stamatelopoulos S, Toumanidis S et al:24h blood pressure profile affects the left ventricle independently of the pressure level. Am J Hypertens 10:168-174, 1997

• 7) Suzuki Y, Kuwajima I, Kanemaru A et al:The cardiac functional reserve in elderly hypertensive patients with abnormal diurnal change in blood pressure. J Hypertens 10:173-179, 1992
  pubmed

• 8) Timio M, Venanzi S, Lolli S et al:"Non-dipper"hypertensive patients and progressive renal insufficiency:A 3-year longitudinal study. Clin Nephrol 43:382-387, 1995
  pubmed

• 9) Floras JS:Antihypertensive treatment, myocardial infarction, and nocturnal myocardial ischaemia. Lancet 2:994-996, 1988
  pubmed

• 10) Mancia G, Di Rienzo M, Parati G:Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension 21:510-524, 1993
  pubmed

• 11) Kario K, Matsuo T, Kobayashi H et al:Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 27:130-135, 1996
  pubmed

• 12) Gosse P, Ansoborlo P, Lemetayer P et al:Left ventricular mass is better correlated with arising blood pressure than with office or occasional blood presssure. Am J Hypertens 10:505-510, 1997
  pubmed

• 13) Panza JA, Epstein SE, Quyyumi AA:Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity.N Engl J Hypertens 325:986-990, 1991

• 14) DeQuattro V, Lee D, Allen J et al:Labetalol blunts morning pressure surge in systolic hypertension. Hypertension 11:1198-1201, 1998

• 15) Pickering TG, Levenstein M, Walmsley P et al:Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure:Results of the HALT study. Am Hypertens 7 844-847, 1994
  pubmed

• 16) Umeda T, Naomi S, Iwaoka T et al:Timing for administration of an antihypertensive drug in the treatment of essential hypertension. (suppl I):S211-S214, 1994

• 17) 桑島巌, 豊島孝道, 中村直人ほか:ドキサゾシンの早朝高血圧に及ぼす影響. 血圧 3:338-393, 1996

• 18) 江畑均, 北條行弘, 池田宇一ほか:血圧日内変動に対するドキサゾシン (カルデナリン錠) の効果-Dipper およびNon-dipperタイプ夜間高血圧に対するα1-blockerの効果-. Ther Res 15:1213-1220, 1994

• 19) 大塚邦明, 山科章, 高尾信廣ほか:過剰降圧を来さないベシル酸アムロジピン降圧効果の時間生物学的評価. 臨床と研究 72:2863-2870, 1995

• 20) 大橋京一, 中島光好:各種降圧薬の効果の持続性とT/Pratioからみた評価. 高血圧の日内リズムからみた病態と管理-その最新知見, 荒川規矩男編. メディカルレビュー社, 大阪, 1996, pp.135-143

• 21) 桑島巌:早朝高血圧:管理の実際. Mebio 15:86-91, 1998

P.202 掲載の参考文献

• 1) Vandenburg H, Kaufman S:In vitro model for stretch-induced hypertrophy of skeletal muscle. Science 203:265-268, 1979

• 2) Yamazaki T, Komuro I, Kudoh S et al:Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. J Clin Invest 96:438-446, 1995
  pubmed

• 3) Takano H, Komuro I, Zou Y et al:Activation of p70 S6 protein kinase is necessary for angiotensin II-induced hypertrophy in neonatal rat cardiac myocytes. FEBS Lett 379:255-259, 1996
  pubmed

• 4) Yamazaki T, Komuro I, Kudoh S et al:Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 271:3221-3228, 1996
  pubmed

• 5) Dahlof B, Pennert K, Hansson L:Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5:95-110, 1992
  pubmed

• 6) Schmieder RE, Martus P, Klingbeil A:Reversal of left ventricular hypertrophy in essential hypertension. A metaanalysis of randomized double-blind studies [see comments]. JAMA 275:1507-1513, 1996

• 7) Monsalve P, Vera O, Perez Acuna F et al:Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. Am Heart J 21:356-361, 1991

• 8) Agabiti-Rosei E, Muiesan ML, Rizzoni D et al:Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin. J Hum Hypertens 6:9-15, 1992
  pubmed

• 9) Corral JL, Lopez NC, Pecorelli A et al:Doxazosin in the treatment of mild or moderate essential hypertension:an echocardiographic study. Am Heart J 121:352-356, 1991
  pubmed

• 10) Neaton JD, Grimm RH Jr, Prineas RJ et al:Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group [see comments]. JAMA 270:713-724, 1993

• 11) Schulman SP, Weiss JL, Becker LC et al:The effects of antihypertensive therapy on left ventricular mass in elderly patients [see comments]. N Engl J Med 322:1350-1356, 1990

• 12) Verdecchia P, Schillaci G, Borgioni C et al:Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48-54, 1998
  pubmed

P.210 掲載の参考文献

• 1) Edvinsson L, McCulloch J, Uddman R:Feline cerebral veins and arteries:comparison of autonomic innervation and vasomotor responses. J Physiol 325:161-173, 1982
  pubmed

• 2) Edvinsson L, MacKenzie ET:Amine mechanisms in the cerebral circulation. Pharmacol Rev 28:275-348, 1977

• 3) Ohta K, Gotoh F, Shimazu K et al:Locus coeruleus stimulation exerts different influences on the dynamic changes of cerebral pial and intraparenchymal vessels. Neurol Res 13:164-167, 1991
  pubmed

• 4) Toda N:αadrenergic receptor subtypes in human, monkey, and dog cerebral arteries. J pharmacol 226:861-868, 1983

• 5) Sakakibara Y, Fujiwara M, Muramatsu T:Pharmacological characterization ofα-adrenoceptors of the dog basilar artery. Arch Pharmacol 319:1-7, 1982

• 6) Tsukahara T, Taniguchi T, Fujiwara M et al:Characterization ofα adrenoceptors in pial arteries of the bovine brain. Arch Pharmacol 324:88-93, 1983

• 7) Sanchez-Merino JA, Arribas S, Arranz A et al:Regulation of noradrenaline release in human cerebral arteries via presynaptic α2-adrenoceptors. Gen Pharmacol 21:859-862, 1990

• 8) Arribas S, Galvan R, Ferrer M et al:Characterization of the subtype of presynaptic α2-adrenoceptors modulating noradrenaline release in cat and bovine cerebral arteries. J Pharm Pharmacol 43:855-859, 1991

• 9) Dalske HF, Harakal C, Sevy RW et al:Catecholamine content and response to norepinephrine of middle cerebral artery. Proc Soc Exp Biol Med 146:718-721, 1974
  pubmed

• 10) Bauknight GC, Faraci FM, Heistad DD:Endothelium-derived relaxing factor modulates noradrenergic constriction of cerebral arterioles in rabbits. Strofee 23:1522-1526, 1992
  pubmed

• 11) Kitazono T, Faraci FM, Heistad DD:Effect of norepinephrine on rat basilar artery in vivo. Am J Physiol 264:H178-H182, 1993
  pubmed

• 12) Hamar J, Kovach AG, Reivich M et al:Effect of phenoxybenzamine on cerebral blood flow and metabolism in the baboon during hemorrhagic shock. Strolee 10:401-407, 1979
  pubmed

• 13) Kissen I, Weiss HR:Effect of peripheral and central a-adrenoceptor blockade on cerebral microvas-cular and blood flow responses to hypoxia. Life Sci 48:1351-1363, 1991

• 14) Raichle ME, Hartman BK, Eichling JO et al:Central noradrenergic regulation of cerebral blood flow and vascular permeability. Proc Natl Acad Sci:3726-3730, 1975
  pubmed

• 15) Rutland MD, Lee TY, Nimmon CC et al:Measurement of the effects of a single dose of prazosin on the cerebral blood flow in hypertensive patients. Postgrad Med 56:818-822, 1980
  pubmed

• 16) Armstead WM, Leffler CW, Busija DW et al:Adrenergic and prostanoid mechanisms in control of cerebral blood flow in hypotensive newborn pigs. Am J Physiol 254:H671-H677, 1988
  pubmed

• 17) Woods SW, Koster K, Krystal JK et al:Yohimbine alters regional cerebral blood flow in panis disorder. Lancet 2:678, 1988

• 18) Sadoshima S, Fujishima M, Yoshida F et al:Cerebral autoregulation in young spontaneously hypertensive rats:effect of sympathetic denervation. Hypertension 7:392-397, 1985
  pubmed

• 19) Sadoshima S, Fujii K, Kusuda K et al:Importance of bilateral sympathetic innervation on cerebral blood flow autoregulation in the thalamus. Brain Res 413:297-301, 1987
  pubmed

• 20) Kitazono T, Faraci FM, Heistad DD:L-Arginine restores dilator responses of the basilar artery to acetyocholine during chronic hypertension. Hypertension 27:893-896, 1995

• 21) Kitazono T, Heistad DD, Faraci FM:ATP-sensitive potassium channels in the basilar artery during chronic hypertension. Hypertension 22:677-681, 1993
  pubmed

• 22) Nishimura Y:Characterization of 5-hydroxytryptamine receptors mediating contractions in basilar arteries from stroke-prone spontaneously hypertensive rats. Br J Pharmacol 117:1325-1333, 1996
  pubmed

• 23) Fujishima M, Omae T:Lower limit of cerebral autoregulation in normotensive and spontaneously hypertensive rats. Experientia 32:1019-1020, 1976
  pubmed

• 24) Shiokawa O, Sadoshima S, Okada Y et al:α-and β-adrenergic receptors of noradrenergic innervation modulates the lower limits of cerebral and cerebellar blood flow autoregulation in spontaneously hypertensive rats. Gerontology 35:106-112, 1989

• 25) Cai H, Ibayashi S, Yao H et al:The α1-adrenoceptor antagonist, doxazosin, modulates the lower limit of autoregulation of cerebral blood flow during hemorrhagi hypotension in anesthetized hyper-tensive rats. Eur J Pharmacol 286:249-253, 1995

• 26) Anwar M, Buchweitz-Milton E, Weiss HR:Effect of prazosin on microvascular perfusion during middle cerebral artery ligation in the rat. Circ Res 63:27-34, 1988
  pubmed

P.219 掲載の参考文献

• 1) Umemura S, Yasuda G, Uchino K et al:Existence of renal alpha1-and alpha2-adrenoceptors in the human kidney:radioligand binding study in membranes from the human renal cortex and medulla. J Hypertens 4(suppl 6):S222-S225, 1986

• 2) Yasuda G, Umemura S, Ishii M:Characterization of bunazosin-sensitive α1-adrenoceptors in human renal medulla. JCardiovasc Pharmacol 30:163-168, 1997

• 3) Neumann P, Grone HJ, Fuchs E:Autoradiographic localization of prazosin and rauwolscine binding sites in the human kidney. Int Urol Nephrol 25:19-28, 1993

• 4) Umemura S, Yamaguchi S, Tamura K et al:Distribution of α1B-adrenergic receptor mRNA expression along rat nephron segments. Kidney Int 51:1548-1552, 1997

• 5) Price DT, Lefkowitz RJ, Caron MG et al:Localization of mRNA for three distinct α1-adrenergic receptor subtypes in human tissues:implications for human α-adrenergic physiology. Mol Pharmacol 45:171-175, 1994

• 6) Ramarao CS, Denker JM, Perez DM et al:Genomic organization and expression of the human α1B-adrenergic receptor. J Biol Chem 267:21936-21945, 1992

• 7) Weinberg DH, Trivedi P, Tan CP et al:Cloning, expression and characterization of humanα-adrenergic receptors αIA, αIB and α1C. Biochem Biophys Res Commun 201:1296-1304, 1994

• 8) Wilner KD, Ziegler MG:Effects of alpha1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension. Am J Cardiol 59:82G-86G, 1987

• 9) Krusell LR, Christensen CK, Pedersen OL:α-Adrenoceptor blockade in patients with mild to moderate hypertension:long-term renal effects of doxazosin. J Cardiovasc Pharmacol 20:440-444, 1992

• 10) Baba T, Tomiyama T, Murabayashi S et al:Renal effects of bunazosin, a newα1-adrenoceptor blocker, in patients with mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 15:826-830, 1990

• 11) De Leeuw PW, Birkenhager WH:Alpha-adrenoceptors and the kidney. J Hypertens 6(suppl 2):S21-S24, 1988

• 12) De Leeuw PW, De Bos R, Van Es PN et al:Effect of sympathetic stimulation and intrarenal alpha-blockade on the secretion of renin by the human kidney. Eur J Clin Invest 15:166-170, 1985
  pubmed

• 13) Penner SB, Stanko CK, Smyth DD:Selective alpha-1 adrenoceptor blockade and renal sodium handling in humans. J Clin Pharmacol 33:1110-1115, 1993
  pubmed

• 14) Lang CC, Choy AMJ, Balfour DJK et al:Prazosin attenuates the natriuretic response to atrial natriuretic factor in man. Kidney Int 42:433-441, 1992

• 15) Lang CC, Rahman AR, Balfour DJK et al:Prazosin blunts the antinatriuretic effect of circulating angiotensin II in man. J Hypertens 10:1387-1395, 1992

• 16) Schmieder RE, Langenfeld MRW, Gatzka CD et al:Impact ofα-versusβ-blockers on hypertensive target organ damage. Am J Hypertens 10:985-991, 1997

• 17) 鹿野昌彦, 川島司郎, 青木孝彦ほか:糖尿病患者に対するdoxazosinの効果-早期糖尿病性腎症とインスリン感受性についての検討-. 医と薬学 33:453-457, 1995
  Medical*Online

• 18) Holdaas H, Hartmann A, Berg KJ et al:Contrasting effects of angiotensin converting inhibitor and alpha-1-antagonist on albuminuria in insulin-dependent diabetes mellitus patients with nephropathy. J Intern Med 237:63-71, 1995
  pubmed

• 19) Giordano M, Sanders LR, Castellino P et al:Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients. Nephron 72:447-453, 1996
  pubmed

• 20) 塩之入洋, 高崎泉, 石川義弘ほか:本態性高血圧症患者および腎障害を伴う高血圧症患者におけるメシル酸ドキサゾシンの単回投与および連続投与による降圧効果と薬物動態の検討. 診療と新薬 25:1427-1439, 1988

• 21) Michel MC, Rump LC:α-Adrenergic regulation of human renal function. Fundam Clin Pharmacol 10:493-503, 1996

P.227 掲載の参考文献

• 1) Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure:The sixth report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC VI). Arch lntern Med 157:2413-2446, 1997

• 2) Guidlines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999

• 3) Levy D, Walmsley P, Path FRC et al:Principal results of the hypertension and lipid trial (HALT):A multicenter study of doxazosin in patients with hypertension. Am Heart J 31:966-973, 1996

• 4) Steinberg PR, Parthasarathy S, Carew TE et al:Beyond cholesterol. Modification of low-density lipoprotein that increase its atherogeniety. N Engl J Med 320:915-924, 1989

• 5) Kume S, Takeya M, Mori T et al:Immunohistochemical and ultrastructual detection of advanced glycation end products in atherosclerotic lessions of human aorta with a novel specific monoclonal antibody. Am J Pathol 147:654-667, 1995

• 6) 山門実:高血圧と動脈硬化. 最新の高血圧治療の考え方. 荻原俊男監修, 先端医学社, 東京, 1998, pp.3-9

• 7) Jansson JH, Johansson B, Boman K et al:Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol 40:321-326, 1991
  pubmed

• 8) Pool JL:Effects of doxazosin on serum lipids:a review of the clinical and molecular basis for altered lipid metabolism. Am Heart 121:251-260, 1991
  pubmed

• 9) 山門実:本態性高血圧症患者におけるNB-818 (レミジルピン) の脂質代謝に及ぼす影響-活性酸素, 過酸化脂質ならびに頸動脈硬化度に及ぼす影響からの検討-. 診療と新薬33:309-320, 1996

• 10) Ferrara LA, Marotta T, Rubba P et al:Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism. Am J Med 80 (suppl 2A):S104-S108, 1986

• 11) 鈴川満雄:Alpha 1遮断薬の脂質代謝に及ぼす影響. 動脈硬化 20:681-690, 1992

• 12) Foxall TL, Shwaery GT, Stucchi AF et al:Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model. Am J Pathol 140:1357-1363, 1992
  pubmed

• 13) Kowala MC, Nicolosi RJ:Effect of doxazosin on plasma lipids and atherogenesis:Apreliminary report. J Cardiovasalar Pharmarol 13 (suppl 2):S45-S49, 1989

• 14) Vashisht R, Sian M, Fronks PJ et al:Long-term reduction of intimal hyperplasia by the selective alpha-1 adrenergic antagonist doxazosin. Br J Surg 79:1285-1288, 1992

• 15) 高野満雄:動脈硬化と過酸化脂質. J Act Oxyg Free Red 2:469-471, 1991

• 16) Kranowski JJ:Oxdant, antioxidants and cardiovascular discase. J Florid MA 78:435-438, 1991

• 17) Uehara Y, Kawabata Y, Shirahase H et al:Radical scavenging properties of indapamide and renal protection in Dahl salt-sensitive rats. Hypertens Res 15:17-28, 1992

• 18) Chait A, Gilmore M, Kawamura M:Inhibition of low density lipoprotein oxidation in vitro by the 6-and 7-hydroxy-metabolites of doxazosin, an α1-adrenergic antihypertensive agent. Am J Hypertens 7:159-167, 1994

• 19) 山門実, 田口淳一, 大野実:Ca拮抗薬の腎保護作用機i序には本薬の糖化反応抑制作用が関与する. 第21回日本高血圧学会総会抄録集, 東京, 1998, p.144

• 20) 高橋敦彦, 久代登志男, 上松瀬勝男:Doxazosin と hydralazineが高血圧自然発症ラットのインスリン感受性と交感神経機能に与える効果. 日腎会誌 40:240-244, 1998